Key result
Dipyridamole MPI detects undiagnosed IHD in ~22% of hemodialysis patients.
Why the study?
The prevalence of undiagnosed ischemic heart disease in hemodialysis patients was considerable and needed assessment using myocardial perfusion imaging.
Does dipyridamole myocardial perfusion imaging detect undiagnosed ischemic heart disease in hemodialysis patients?
Comparison
IHD-positive group vs IHD-negative group based on dipyridamole MPI
Design
Cross-sectional descriptive study
Authors
Loading...
May support targeted ischemia screening in high-risk hemodialysis patients; leaves open whether detection improves outcomes.
Cross-Sectional (n=69)
Does dipyridamole myocardial perfusion imaging detect undiagnosed ischemic heart disease in hemodialysis patients?
Dipyridamole myocardial perfusion imaging reveals a considerable prevalence (21.7%) of undiagnosed ischemic heart disease in hemodialysis patients, particularly those with traditional and uremia-specific risk factors.
Nikparvar et al. (2015) conducted a cross-sectional in Hemodialysis (n=69). Dipyridamole myocardial perfusion imaging (MPI) was evaluated on Undiagnosed ischemic heart disease (IHD). Dipyridamole myocardial perfusion imaging detected undiagnosed ischemic heart disease in 21.7% of hemodialysis patients, with higher prevalence linked to diabetes, hypertension, and aging (P<0.05).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: